1.08
-0.05(-4.42%)
Currency In USD
| Previous Close | 1.13 |
| Open | 1.13 |
| Day High | 1.15 |
| Day Low | 1.06 |
| 52-Week High | 5.66 |
| 52-Week Low | 1.04 |
| Volume | 2.45M |
| Average Volume | 5.54M |
| Market Cap | 154.24M |
| PE | -4 |
| EPS | -0.27 |
| Moving Average 50 Days | 1.38 |
| Moving Average 200 Days | 1.86 |
| Change | -0.05 |
If you invested $1000 in Humacyte, Inc. (HUMA) since IPO date, it would be worth $111.69 as of December 25, 2025 at a share price of $1.08. Whereas If you bought $1000 worth of Humacyte, Inc. (HUMA) shares 3 years ago, it would be worth $524.27 as of December 25, 2025 at a share price of $1.08.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair
GlobeNewswire Inc.
Dec 22, 2025 1:00 PM GMT
- Results published in Journal of Vascular Surgery Cases, Innovations and Techniques (JVS-CIT) - - After up to 36 months of follow-up, patients demonstrated high limb salvage, low rates of infection, no unprovoked structural failures - - Results re
Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital
GlobeNewswire Inc.
Dec 16, 2025 1:00 PM GMT
DURHAM, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has entere
Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results
GlobeNewswire Inc.
Nov 20, 2025 1:00 PM GMT
– Post-implantation analysis of ATEVs demonstrates progressive recellularization with host cells, transforming the ATEV into a multi-layered living tissue similar to that of native blood vessels – – Positive outcomes for dialysis patients sufferin